| Literature DB >> 11483849 |
J M Kramer1, P LaRussa, W C Tsai, P Carney, S M Leber, S Gahagan, S Steinberg, R A Blackwood.
Abstract
The Food and Drug Administration licensed a live-virus varicella vaccine (Varivax; Merck & Co Inc, West Point, PA) in March 1995. Prelicensure adverse events were minimal; however, since licensure and increased vaccine use, rare previously undetected risks have arisen. Presented here is the clinical course of a previously undiagnosed, human immunodeficiency virus-infected boy who developed dissemination of the vaccine strain of varicella zoster after immunization. chickenpox, human immunodeficiency virus, pneumonia, encephalopathy, varicella vaccine, adverse events, dissemination.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11483849 DOI: 10.1542/peds.108.2.e39
Source DB: PubMed Journal: Pediatrics ISSN: 0031-4005 Impact factor: 7.124